Showing results (71-80 of 129) with videos related to

Sort By:
Pageof 13
Antiviral Therapy|October 11, 2012
A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patientsEric J Lawitz, John M Hill, Thomas Marbury, et al.
Antiviral Research|June 15, 2007
Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitroLiangjun Lu, Tatyana Dekhtyar, Sherie Masse, et al.
Journal of Hepatology|December 8, 2016
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvirDavid Wyles, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.
The Lancet. Microbe|April 13, 2026
Classification and sequencing of hepatitis D virus from a large cohort of chronically infected individuals paired with co-infecting hepatitis B virus sequencing: a genomic characterisation studySavrina Manhas, Silvia Chang, Ross Martin, et al.
Antiviral Therapy|October 7, 2015
The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular diseaseTracey G Simon, Arthur Y Kim, Luisa M Stamm, et al.
Antiviral Therapy|June 27, 2017
Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvirDavid Wyles, Alessandra Mangia, Wendy Cheng, et al.
The Journal of Infectious Diseases|November 26, 2015
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B SubstitutionsEvguenia S Svarovskaia, Edward Gane, Hadas Dvory-Sobol, et al.
Hepatology (Baltimore, Md.)|August 8, 2014
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirinCharlotte Hedskog, Brian Doehle, Krishna Chodavarapu, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2005
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitroHongmei Mo, Liangjun Lu, Tami Pilot-Matias, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 24, 2021
Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in RussiaVasily Isakov, Charlotte Hedskog, Joel O Wertheim, et al.
Pageof 13